This study represents an important step toward the development of alternative therapies for patients with ELANE mutations, particularly those who respond poorly to G-CSF and are at increased risk of progression to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This evidence concerns the gene CSF3 and acute myeloid leukemia.